Clrpharmaceuticals

Palwal, Haryana

Durvalumab[1] (trade name imfinzi) is an fda-approved immunotherapy for cancer,  developed by medimmune/astrazeneca.[2] it is a human immunoglobulin g1 kappa (igg1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (pd-l1) with the pd-1 (cd279). Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

• MOQ 1 22
• Packaging SizeOther
• Packaging TypeOther
• PurityOther
• CancerBreast cancer medicine

Olaparib is an FDA-approved targeted therapy for cancer. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers

• ConditionNew
• Blood cancer medicineCml medicine